Navigation Links
Neuralstem Receives Notice Of Issuance For Patent Covering Human Neural Cell Transplantation For Neurodegenerative Conditions
Date:7/26/2012

ROCKVILLE, Md., July 26, 2012 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) announced that it received a notice of issuance for patent number 12/710,097 titled: "Transplantation of Human Neural Cells for Treatment of Neurodegenerative Conditions." This patent covers both the culturing of central nervous system cells as well as their transplantation into spinal cord tissue to treat neurodegenerative conditions, including amytrophic lateral sclerosis (ALS or Lou Gehrig's disease). Neuralstem is currently conducting a Phase I safety trial of its human spinal cord stem cells in the treatment of ALS.

(Logo: http://photos.prnewswire.com/prnh/20061221/DCTH007LOGO )

"This is a major addition to our patent estate," said Neuralstem Chairman & Chief Scientific Officer, Karl Johe, PhD. "This patent includes claims covering processes for dissociating our neural stem cells from central nervous system tissue; culturing the cells; expanding the cells in vitro and transplanting the neural stem cells into the spinal cord of a patient to treat a wide array of neurodegenerative conditions including, amyotrophic lateral sclerosis (ALS)."

"We are pleased to have this new patent issued, which will expire in Q1 2030," said Neuralstem President & CEO, Richard Garr. "We have currently transplanted 17 patients in our ALS trial and we have been encouraged by the results so far.  We are focused on this program as our first potential transplantation product.  We believe that having this specific patent coverage as well as this patent life into 2030 is reflective of the value we are creating in our cell therapy programs."

About Neuralstem

Neuralstem's patented technology enables the ability to produce neural stem cells of the human brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells constitutively into mature, physiologically relevant human neurons and glia. Neuralstem is in an FDA-approved Phase I safety clinical trial for amyotrophic lateral sclerosis (ALS), often referred to as Lou Gehrig's disease, and has been awarded orphan status designation by the FDA.

In addition to ALS, the company is also targeting major central nervous system conditions with its cell therapy platform, including spinal cord injury, ischemic spastic paraplegia and chronic stroke. The company has submitted an IND (Investigational New Drug) application to the FDA for a Phase I safety trial in chronic spinal cord injury.

Neuralstem also has the ability to generate stable human neural stem cell lines suitable for the systematic screening of large chemical libraries. Through this proprietary screening technology, Neuralstem has discovered and patented compounds that may stimulate the brain's capacity to generate new neurons, possibly reversing the pathologies of some central nervous system conditions.  The company is in a Phase Ib safety trial evaluating NSI-189, its first neurogenic small molecule compound, for the treatment of major depressive disorder (MDD).  Additional indications could include CTE (chronic traumatic encephalopathy), Alzheimer's disease, anxiety, and memory disorders.

For more information, please visit www.neuralstem.com or connect with us on Twitter and Facebook.

Cautionary Statement Regarding Forward Looking Information

This news release may contain forward-looking statements made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements in this press release regarding potential applications of Neuralstem's technologies constitute forward-looking statements that involve risks and uncertainties, including, without limitation, risks inherent in the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for future capital, dependence upon collaborators and maintenance of our intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in Neuralstem's periodic reports, including the annual report on Form 10-K for the year ended December 31, 2011 or the Form 10-Q for the period ended March 30, 2012.


'/>"/>
SOURCE Neuralstem, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Neuralstem ALS Stem Cell Trial Featured on Fox Atlanta
2. Neuralstem President and CEO to Update Ongoing ALS and NSI-189/Major Depressive Disorder Trials at 2012 Biotech Showcase
3. Neuralstem President and CEO to Present at BIO CEO & Investor Conference 2012
4. Neuralstem Announces Closing of $5.2-Million Registered Direct Offering
5. Fourteenth Patient Dosed in Neuralstem ALS Stem Cell Trial
6. Neuralstem CEO to Present at the World Stem Cells and Regenerative Medicine Congress in London
7. UCSB professor receives award for graphene electronics research
8. Watsons Generic Yaz(R) Receives FDA Approval
9. Quanterix Receives Funding From the Department of Homeland Security to Develop Test for Botulinum Toxin
10. Life Technologies Ion Personal Genome Machine Receives San Diegos CONNECT Most Innovative New Product Award
11. MacroGenics Receives Milestone Payment as Part of Its Global DART™ Alliance with Boehringer Ingelheim
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... (PRWEB) , ... October 12, ... ... today announces publication of a United States multicenter, prospective clinical study that ... disposable, point-of-care diagnostic test capable of identifying clinically significant acute bacterial and ...
(Date:10/11/2017)... ... 2017 , ... At its national board meeting in North ... the co-founder, CEO and chief research scientist of Minnesota-based Advanced Space Technology and ... ARCS Alumni Hall of Fame . ASTER Labs is a technology development ...
(Date:10/11/2017)... , ... October 11, 2017 , ... ... announced today it will be hosting a Webinar titled, “Pathology is going digital. ... Associates , on digital pathology adoption best practices and how Proscia improves lab ...
(Date:10/11/2017)... ... October 11, 2017 , ... A ... pregnancy rates in frozen and fresh in vitro fertilization (IVF) transfer ... age to IVF success. , After comparing the results from the fresh and ...
Breaking Biology Technology:
(Date:3/30/2017)... ANGELES , March 30, 2017  On April ... Hack the Genome hackathon at Microsoft,s ... exciting two-day competition will focus on developing health and ... Hack the Genome is the ... been tremendous. The world,s largest companies in the genomics, ...
(Date:3/28/2017)... 2017 The report "Video Surveillance ... Servers, Storage Devices), Software (Video Analytics, VMS), and Service ... Forecast to 2022", published by MarketsandMarkets, the market was ... projected to reach USD 75.64 Billion by 2022, at ... base year considered for the study is 2016 and ...
(Date:3/23/2017)... , March 23, 2017 The report "Gesture Recognition ... Biometric), Industry, and Geography - Global Forecast to 2022", published by MarketsandMarkets, the ... a CAGR of 29.63% between 2017 and 2022. ... ... ...
Breaking Biology News(10 mins):